Sa1943 ESG PLUS LIRAGLUTIDE IS SUPERIOR TO ESG ALONE FOR WEIGHT LOSS IN OVERWEIGHT AND OBESE PATIENTS

The global epidemic of overweight and obesity – termed “globesity”, is an escalating public health problem. It is crucial that bariatric endoscopists innovate, and procedures evolve to produce more effective and less invasive therapies. Endoscopic Sleeve Gastroplasty (ESG) is an incisionless, minimally invasive Endoscopic Bariatric Therap y (EBT) that involves remodeling the greater curvature of the stomach by placement of full-thickness sutures. Percent total body weight loss (%TBWL) at 12 months following ESG is 16.5% compared to 3-7.5% with weight loss medications.

Source: Gastrointestinal Endoscopy - May 31, 2020 Category: Gastroenterology Authors: Dilhana Badurdeen, Anna Carolina Hoff, Abdellah Hedjoudje, Mohamad I. Itani, Jad Farha, Anthony N. Kalloo, Mouen A. Khashab, Manoel Galvao Neto, Sergio A. Barrichello, Vivek Kumbhari Tags: Poster abstracts Source Type: research